The EMA validation of T-DXd with pertuzumab could change the standard of care for HER2-positive metastatic breast cancer in treatment-naive patients. DESTINY-Breast09 trial data showed significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results